Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
AnimalPharm
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Legislation
|
Business
|
Products
|
Generics - Products
About Us
Getting Started
Subscribe
Free Trial
Advertise
Awards
White Papers
Executive Briefing
Classifieds
Recruitment
JOB OF THE WEEK
Promote your vacancy here
SCRIP's ONLINE DIRECTORY
Classified ads
LATEST NEWS
Pfizer withdraws Macugen for DMO in Europe
19 July 2011
Gilenya and Tasigna drive new product growth at Novartis...
EMA confirms Champix' positive benefit-risk balance, but wil...
Merck Serono ditches cladribine, leaving MS franchise exposed
22 June 2011
Hungary's Egis raised Q1 sales up 16%
02 March 2011
EU new drug approvals down sharply in 2010
11 January 2011
Russia introduces mandatory price registration for vital and essential drugs
03 March 2010
>> More News...
LATEST ANALYSIS
Challenges and opportunities in the Philippine pharma market
08 January 2010
Executive Briefing – Health technology assessment: a brief look at the EU
31 December 2009
2010 Scrip 100 - Rich pickings for biosimilars?
09 December 2009
>> More Analysis...
LATEST FEATURES
Anti-obesity drugs: an inventor's perspective
20 November 2009
Interview: Russian pharma needs to tap foreign markets to boost its development
01 June 2009
>> More Features...
LATEST COMMENT
Dapagliflozin: 'No' from FDA advisers could spell trouble for new diabetes class
21 July 2011
Commentary: ECJ ruling on pre-accession authorisations has implications for industry
03 July 2009
Commentary: From boardroom to courtroom: maximising your return - by Hitesh Patel and Simon tottman of KPMG
21 July 2008
>> More Comment...
REFINE BY
COMPANY/ORGANISATION
PFIZER
NOVARTIS
GLAXOSMITHKLINE
SANOFI-AVENTIS
CONDITION
CANCER
PAIN
DIABETES
ARTHRITIS
GEOGRAPHY
JAPAN
GERMANY
INDIA
CHINA
DRUG
SIMVASTATIN
BEVACIZUMAB
AMLODIPINE
INFLIXIMAB
